| apixaban 2.5mg versus discontinuation | |||
| AMPLIFY-EXT 2.5mg, 2012 NCT00633893 | Extended Treatment with apixaban 2.5 mg twice daily 12 months versus placebo | patients who have completed their intended treatment for deep vein thrombosis or pulmonary embolism | double blind Follow-up duration: 12 mo |
| apixaban 5mg versus discontinuation | |||
| AMPLIFY-EXT 5mg, 2012 NCT00633893 | Extended Treatment with apixaban 5 mg twice daily 12 months
versus placebo | patients who have completed their intended treatment for deep vein thrombosis or pulmonary embolism | double blind Follow-up duration: 12 mo |
| aspirin versus discontinuation | |||
| WARFASA, 2012 NCT00222677 | aspirin, 100 mg daily for 2 years versus placebo | patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment | double-blind Follow-up duration: 24.6 mo (median) |
| ASPIRE, 2012 ACTRN12605000004662 | aspirin, at a
dose of 100 mg daily up to 4 years versus | patients who had completed initial anticoagulant therapy after a first episode of unprovoked venous thromboembolism | Follow-up duration: 37.2 montsh (median) |
| dabigatran versus discontinuation | |||
| RE-SONATE, 2011 NCT00558259 | dabigatran 150 mg twice daily for an additional period of 6 months versus placebo | Secondary prevention of VTE in patients with VTE who had completed 6-18 months of anticoagulant therapy | double-blind |
| dabigatran versus warfarin | |||
| RE-MEDY, 2011 NCT00329238 | dabigatran 150 mg twice daily for an additional period of 6 to 36 months versus warfarin (to maintain an international normalized ratio of 2.0 to 3.0) for an additional period of 6 to 36 months | Secondary prevention of VTE in patients with VTE who had initially received 3 to 12 months of anticoagulant therapy | double-blind Follow-up duration: 6 to 36 months |
| idraparinux versus discontinuation | |||
| VanGogh extension, 2007 NCT00071279 | once-weekly injections of 2.5 mg of idraparinux for 6 months versus placebo | patients who had completed 6 months of prophylaxis with idraparinux or a vitamin K antagonist and in whom extended anticoagulation was warranted | Follow-up duration: 6 months |
| rivaroxaban versus discontinuation | |||
| EINSTEIN-extension, 2009 NCT00439725 | rivaroxaban 20 mg once-daily for an additional 6 or 12 months versus placebo | patients who had completed six to 12 months of anticoagulant treatment for an acute episode of VTE | double blind 28 countries |
| warfarin versus discontinuation | |||
| PROLONG (Palareti), 2006 NCT00264277 | prolongation versus no anticoagulation | patients with an abnormal d-dimer level 1 month after the discontinuation of anticoagulation in patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months | Follow-up duration: 1.4 yeras |
| PREVENT (Ridker), 2003 | extension with low-intensity warfarin (target INR, 1.5 to 2.0) versus placebo | Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months | Follow-up duration: 2.1 years |
| Agnelli, 2003 | continuation for 3 or 9 additionnal months of warfarin or other oral anticoagulant was adjusted to achieve a target INR between 2.0 and 3.0. versus discontinuation (after 3 months) | patients who had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding after a first episode of pulmonary embolism | open Follow-up duration: 33 months Italy |
| Agnelli, 2001 | continuation for 9 additional months; warfarin or acenocoumarol adjusted to achieve a target INR between 2.0 and 3.0 versus discontinuation (after 3 months months) | Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy | open Follow-up duration: 33 months Italy |
| LAFIT (Kearon), 1999 | Continuation of the oral anticoagulant therapy up to 24 months,
warfarin was adjusted to achieve
a target INR between 2.0 and 3.0. versus discontinuation (after 3 months) | patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism | |
| Levine, 1995 | continuation for 2 months of warfarin adjusted INR value of 2.0 to 3.0 versus Discontinue oral anticoagulant therapy (after 1 months) | Patients with venographically confirmed acute proximal DVT who had received four weeks of warfarin after initial heparin and whose four week IPG was normal | double blind Follow-up duration: 11 months after randomization. Canada, Italy |
| DURAC (Schulman), 1997 | indefinite warfarin or dicoumarol adjusted for a target INR between 2.0 and 2.85 versus 6 months warfarin or dicoumarol adjusted for a target INR between 2.0 and 2.85 | open Follow-up duration: Four years after randomization Sweden | |
| ximelagatran versus discontinuation | |||
| THRIVE III, 2003 | ximelagatran 24 mg twice daily for 18 months versus placebo for 18 months | patients with venous thromboembolism who had undergone six months of anticoagulant therapy | double blind Follow-up duration: 18 months 18 countries |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
